An autocrine loop for vascular endothelial growth factor is established in prostate cancer cells generated after prolonged treatment with interleukin 6

European Journal of Cancer

Volumn 40, Issue 7, 2004, Pages 1066-1072

  Steiner, Hannes ^a   Berger, Andreas P ^a   Godoy Tundidor, S ^a   Bjartell, A ^b   Lilja, H ^b   Bartsch, G ^a   Hobisch, A ^a,c   Culig, Z ^a  

^a INNSBRUCK MEDICAL UNIVERSITY   (Austria)

^b LUND UNIVERSITY   (Sweden)

^c General Hospital Feldkirch   (Austria)

Author keywords

Autocrine signalling; Cytokines; Interleukin 6; Prostate cancer; Vascular endothelial growth factor

Indexed keywords

INTERLEUKIN 6; NEUTRALIZING ANTIBODY; PHOSPHOTRANSFERASE; VASCULOTROPIN; VASCULOTROPIN RECEPTOR 2;

ARTICLE; AUTOCRINE EFFECT; CELL PROLIFERATION; CELL STIMULATION; CELL STRAIN; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; HUMAN CELL; MEASUREMENT; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN DETERMINATION; REGULATORY MECHANISM; SUPERNATANT; TUMOR GROWTH; UPREGULATION;

AUTOCRINE COMMUNICATION; BLOTTING, WESTERN; CELL DIVISION; CELL LINE, TUMOR; HUMANS; INTERLEUKIN-6; MALE; PROSTATIC NEOPLASMS; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2;

EID: 1942517751     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejca.2003.11.033     Document Type: Article

References (33)

1. Culig Z., Bartsch G., Hobisch A. Interleukin-6 regulates androgen receptor activity and prostate cancer cell growth. Mol. Cell. Endocrinol. 197:2002;231-238.
2. Degeorges A., Tatoud R., Fauvel Lafeve F.et al. Stromal cells from human benign prostate hyperplasia produce a growth-inhibitory factor for LNCaP prostate cancer cells, identified as interleukin-6. Int. J. Cancer. 68:1996;207-214.
3. Qiu Y., Ravi L., Kung H.J. Requirement of ErbB2 for signalling by interleukin-6 in prostate carcinoma cells. Nature. 393:1998;83-85.
4. Hobisch A., Ramoner R., Fuchs D.et al. Prostate cancer cells (LNCaP) generated after long-term interleukin-6 treatment express interleukin-6 and acquire an interleukin-6-partially resistant phenotype. Clin. Cancer Res. 7:2001;2941-2948.
5. Giri D., Ozen M., Ittmann M. Interleukin-6 is an autocrine growth factor in human prostate cancer. Am. J. Pathol. 159:2001;159-165.
6. Twillie D.A., Eisenberger M.A., Carducci M.A., Hseih W.-S., Kim W.Y., Simons J.W. Interleukin-6. a candidate mediator of human prostate cancer morbidity Urology. 45:1995;542-549.
7. Steiner H., Godoy-Tundidor S., Rogatsch H.et al. Accelerated in vivo growth of prostate tumors that up-regulate interleukin-6 is associated with reduced retinoblastoma protein expression and activation of the mitogen-activated protein kinase pathway. Am. J. Pathol. 162:2003;655-663.
8. Masood R., Cai J., Zheng T., Smith D.L., Naidu Y., Gill P.S. Vascular endothelial growth factor/vascular permeability factor is an autocrine growth factor for AIDS-Kaposi sarcoma. Proc. Natl. Acad. Sci. U.S.A. 94:1997;979-984.
9. Soker S., Kaefer M., Johnson M., Klagsbrun M., Atala A., Freeman M.R. Vascular endothelial growth factor-mediated autocrine stimulation of prostate tumor cells coincides with progression to a malignant phenotype. Am. J. Pathol. 159:2001;651-659.
10. Jackson M.W., Roberts J.S., Heckford S.E.et al. A potential autocrine role for vascular endothelial growth factor in prostate cancer. Cancer Res. 62:2002;854-859.
11. Duque J.L., Loughlin K.R., Adam R.M., Kantoff P.W., Zurakowski D., Freeman M.R. Plasma levels of vascular endothelial growth factor are increased in patients with metastatic prostate cancer. Urology. 54:1999;523-527.
12. Chen H.J., Treweeke A.T., Ke Y.Q., West D.C., Toh C.H. Angiogenically active vascular endothelial growth factor is over-expressed in malignant human and rat prostate carcinoma cells. Br. J. Cancer. 82:2000;1694-1701.
13. Balbay M.D., Pettaway C.A., Kuniyasu H.et al. Highly metastatic human prostate cancer growing within the prostate of athymic mice overexpresses vascular endothelial growth factor. Clin. Cancer Res. 5:1999;783-789.
14. Cohen T., Nahari D., Cerem L.W., Neufeld G., Levi B.Z. Interleukin 6 induces the expression of vascular endothelial growth factor. J. Biol. Chem. 271:1996;736-741.
15. Bradford M. A rapid and sensitive method for the quantitation of microgram quantities of protein using the principle of protein-dye binding. Anal. Biochem. 72:1978;248-254.
16. Joseph I.B., Nelson J.B., Denmeade S.R., Isaacs J.T. Androgens regulate vascular endothelial growth factor content in normal and malignant prostatic tissue. Clin. Cancer Res. 3:1997;2507-2511.
17. Sordello S., Bertrand N., Plouet J. Vascular endothelial growth factor is up-regulated in vitro and in vivo by androgens. Biochem. Biophys. Res. Commun. 251:1998;287-290.
18. Funamoto T., Fujio Y., Kunisada K.et al. Signal transducer and activator of transcription 3 is required for glycoprotein 130-mediated induction of vascular endothelial growth factor in cardiac myocytes. J. Biol. Chem. 275:2000;10561-10566.
19. Burroughs K.D., Oh J., Barrett J.C., DiAugustine R.P. Phosphatidylinositol 3-kinase and mek 1/2 are necessary for insulin-like growth factor-I-induced vascular endothelial growth factor synthesis in prostate epithelial cells. a role for hypoxia-inducible factor-1? Mol. Cancer Res. 1:2003;312-322.
20. Liu X.H., Kirschenbaum A., Lu M.et al. Prostaglandin E(2) stimulates prostatic intraepithelial neoplasia cell growth through activation of the interleukin-6/GP130/STAT-3 signaling pathway. Biochem. Biophys. Res. Commun. 290:2002;249-255.
21. Chung T.D., Yu J.J., Spiotto M.T., Bartkowski M., Simons J.W. Characterization of the role of IL-6 in the progression of prostate cancer. Prostate. 38:1999;199-207.
22. Smith P.C., Keller E.T. Anti-interleukin-6 monoclonal antibody induces regression of human prostate cancer xenografts in nude mice. Prostate. 48:2001;47-53.
23. Levesque E., Beaulieum M., Guillemette C., Hum D.W., Belanger A. Effect of interleukins on UGT2B15 and UGT2B17 steroid uridine diphosphate- glucuronosyltransferase expression and activity in the LNCaP cell line. Endocrinology. 139:1998;2375-2381.
24. Banerjee S., Saxena N., Sengupta K., Banerjee S.K. 17alpha-estradiol VEGF-A expression in rat pituitary tumor cells is mediated through ER independent but PI3K-Akt dependent signaling pathway. Biochem. Biophys. Res. Commun. 300:2003;209-215.
25. Ferrer F.A., Miller L.J., Lindquist R.et al. Expression of vascular endothelial growth factor receptors in human prostate cancer. Urology. 54:1999;567-572.
26. Haggstrom S., Lissbrandt I.F., Bergh A., Damber J.E. Testosterone induces vascular endothelial growth factor synthesis in the ventral prostate in castrated rats. J. Urol. 161:1999;1620-1625.
27. Kollermann J., Helpap B. Expression of vascular endothelial growth factor (VEGF) and VEGF receptor Flk-1 in benign, premalignant, and malignant prostate tissue. Am. J. Clin. Pathol. 116:2001;115-121.
28. Ferrer F.A., Miller L.J., Andrawis R.I.et al. Vascular endothelial growth factor (VEGF) expression in human prostate cancer. in situ and in vitro expression of VEGF by human prostate cancer cells J. Urol. 157:1997;2329-2333.
29. Sweeney P., Karashima T., Kim S.J.et al. Anti-vascular endothelial growth factor receptor 2 antibody reduces tumorigenicity and metastasis in orthotopic prostate cancer xenografts via induction of endothelial cell apoptosis and reduction of endothelial cell metalloproteinase type 9 production. Clin. Cancer Res. 8:2002;2714-2724.
30. Fox W.D., Higgins B., Malese K.M.et al. Antibody to vascular endothelial growth factor slows growth of and androgen-independent xenograft model of prostate cancer. Clin. Cancer Res. 8:2002;3226-3231.
31. Boocock C.A., Charnock-Jones D.S., Sharkey A.M.et al. Expression of vascular endothelial growth factor and its receptors flt and KDR in ovarian carcinoma. J. Natl. Cancer Inst. 87:1995;506-516.
32. Bachelder R.E., Crago A., Chung J.et al. Vascular endothelial growth factor is an autocrine survival factor for neuropilin-expressing breast carcinoma cells. Cancer Res. 61:2001;5736-5740.
33. von Marschall Z., Cramer T., Hocker M.et al. De novo expression of vascular endothelial growth factor in human pancreatic cancer. evidence for an autocrine mitogenic loop Gastroenterology. 119:2000;1358-1372.